Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
Open Access
- 23 August 2025
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 36 (11) , 1409-1413
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute
- Sanofi
- National Institutes of Health (UG1CA189829)
- National Institutes of Health (UG1CA233339)
- National Institutes of Health (U10CA180794)
- National Institutes of Health (UG1CA233193)
- National Institutes of Health (UG1CA233196)
- National Institutes of Health (UG1CA233277)
- National Institutes of Health (UG1CA233180)
- National Institutes of Health (U10CA180821)
- National Institutes of Health (UG1CA233234)
- National Institutes of Health (UG1CA233320)
- National Institutes of Health (UG1CA233270)
- National Institutes of Health (U10CA180888)
- National Institutes of Health (U10CA180820)
This publication has 14 references indexed in Scilit:
- Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS StudyEuropean Urology, 2024
- Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trialsThe Lancet Oncology, 2023
- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialThe Lancet Oncology, 2023
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancerAnnals of Oncology, 2023
- Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial designThe Lancet, 2022
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerNew England Journal of Medicine, 2019
- Apalutamide for Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2019
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013